Andrea Corcoran
Director of Finance/CFO at ATEA PHARMACEUTICALS, INC.
Net worth: 2 M $ as of 29/04/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jean-Pierre Sommadossi | M | 68 | 25 years | |
| Franklin Berger | M | 74 | 5 years | |
| Maria Horga | M | 55 | 4 years | |
| Jonae R. Barnes | F | - | 3 years | |
| Bruno Lucidi | M | 64 | 10 years | |
| Paul J. Fanning | M | 66 | 11 years | |
| Bruce Polsky | M | 70 | 10 years | |
| Jerome Adams | M | 49 | 3 years | |
| Barbara Duncan | F | 59 | 4 years | |
| Wayne Foster | M | 55 | 5 years | |
| Keith Pietropaolo | M | - | 12 years | |
| Polly Murphy | M | 59 | 4 years | |
| Laura Ishak | F | - | - | |
| Jayanthi Wolf | M | - | 3 years | |
| Ariyapadi N. Krishnaraj | M | - | - | |
| Adel Moussa | M | - | 22 years | |
| John Vavricka | M | 60 | 6 years | |
| Janet Hammond | M | 64 | 4 years | |
| Brian Rowe | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Douglas Beck | M | 62 | 2 years | |
| Tom R. Hodgson | M | 82 | 12 years | |
| Charles W. Cramb | M | 77 | 9 years | |
| Dominique Surleraux | M | - | - | |
| David N. Standring | M | 73 | 13 years | |
| David Arkowitz | M | 62 | 4 years | |
| Andrew Hack | M | 50 | 1 years | |
| Pamela Bassett | M | - | 1 years | |
| Frederick Larcombe | M | 67 | 2 years | |
| Jules Müsing | M | 76 | 2 years | |
| Denise Scots-Knight | M | 64 | 11 years | |
| Wayne T. Hockmeyer | M | 79 | - | |
| Brian Fenton | M | 57 | 5 years | |
| Donna M. Jarlenski | F | - |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 2 years |
| Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Kai Lin | M | - | - | |
| Nathanial Brown | M | - | - | |
| Claudio Avila | M | - | 1 years | |
| Grigory G. Borisenko | M | 55 | 1 years | |
| Fan Yu | M | - | 3 years | |
| Donald Mitchell | M | - | 3 years | |
| Meredith Fisher | M | - | 1 years | |
| Mary E. Taylor | F | 65 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
| Aoife Brennan | M | 48 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 years |
| Christopher Rovaldi | M | 50 | 3 years | |
| Isaac Cheng | M | 49 | 2 years | |
| David Hallinan | M | - | - | |
| Teresa Regan | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| David J. Franklin | M | - | 8 years | |
| Daniel Char | M | 63 | 1 years | |
| Thomas Ebeling | M | 65 | - | |
| Robert E. Pelzer | M | 70 | 9 years | |
| Susan L. Koppy | F | 62 | 1 years | |
| John F. Weidenbruch | M | 63 | 4 years | |
| Norman Payson | M | 49 | 2 years | |
| Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 years |
| Ansbert Gadicke | M | 66 | 7 years | |
| Robert Blanks | M | 64 | 3 years | |
| Elizabeth Czerepak | F | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 years |
| Antonin Rollet de Fougerolles | M | 59 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 1 years |
| Bihua Chen | F | 55 | - | |
| James J. Egan | M | 73 | 5 years | |
| Guy MacDonald | M | 65 | 5 years | |
| Alexandra Goll | M | 68 | - | |
| Pamela Thomas-Graham | F | 60 | 5 years | |
| Raymond Schinazi | M | 74 | - | |
| Ian McLeod | M | - | 3 years | |
| Kevin J. Slatkavitz | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 67 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrea Corcoran
- Personal Network
